ALOX5 promoter genotype and response to montelukast in moderate persistent asthma

Respiratory Medicine

Volumn 102, Issue 6, 2008, Pages 857-861

  Telleria, Juan J ^a   Blanco Quiros, Alfredo ^a   Varillas, David ^a   Armentia, Alicia ^b   Fernandez Carvajal, Isabel ^a   Jesus Alonso, M ^a   Diez, Ignacio ^c  

^a UNIVERSITY OF VALLADOLID   (Spain)

^b HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^c HOSPITAL TXAGORRITXU   (Spain)

Author keywords

5 Lipoxygenase; Asthma; Leukotrienes; Pharmacogenetics; Response rate

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; MONTELUKAST;

ADD ON THERAPY; ADOLESCENT; ADULT; ALLELE; ARTICLE; ASTHMA; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; TANDEM REPEAT; TREATMENT DURATION;

ACETATES; ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTI-ASTHMATIC AGENTS; ARACHIDONATE 5-LIPOXYGENASE; ASTHMA; FEMALE; FORCED EXPIRATORY VOLUME; GENOTYPE; HUMANS; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); QUINOLINES; SEX DISTRIBUTION; TANDEM REPEAT SEQUENCES; TREATMENT OUTCOME;

EID: 43049122378     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2008.01.011     Document Type: Article

References (17)

1. Drazen J.M., Israel E., and O'Byrne P.M. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 340 (1999) 197-206
2. Woods J.W., Evans J.F., Ethier D., Scott S., Vickers P.J., Hearn L., et al. 5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes. J Exp Med 178 (1993) 1935-1946
3. Drazen J.M., Silverman E.K., and Lee T.H. Heterogeneity of therapeutic responses in asthma. Br Med Bull 56 (2000) 1054-1070
4. Hall I.P., and Sayers Y. Pharmacogenetics and asthma: false hope or new dawn?. Eur Resp J 29 (2007) 1239-1245
5. In K.H., Asano K., Beier D., Grobholz J., Finn P.W., Silverman E.K., et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 99 (1997) 1130-1137
6. Drazen J.M., Yandava C.N., Dube L., Szczerback N., Hippensteel R., Pillari A., et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 22 (1999) 168-170
7. Masoli M., Fabian D., Holt S., Beasley R., and Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 59 (2004) 469-478
8. Pauwels R.A., Lofdahl C.G., Postma D.S., Tattersfield A.E., O'Byrne P., Barnes P.J., et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 337 (1997) 1405-1411
9. Sayers I., Barton S., Rorke S., Sawyer J., Peng Q., Beghe B., et al. Promoter polymorphism in the 5-lipoxygenase (ALOX5) and 5-lipoxygenase-activating protein (ALOX5AP) genes and asthma susceptibility in a Caucasian population. Clin Exp Allergy 33 (2003) 1103-1110
10. Leff A.R. Regulation of leukotrienes in the management of asthma: biology and clinical therapy. Annu Rev Med 52 (2001) 1-14
11. Wechsler M.E. Managing asthma in the 21st century: role of pharmacogenetics. Pediatr Ann 35 (2006) 664-669
12. Szczeklik A., Mastalerz L., Nizankowska E., and Sanak M. Myocardial ischemia possibly mediated by cysteinyl leukotrienes. J Allergy Clin Immunol 109 (2002) 572-573
13. Sampson A.P., Siddiqui S., Buchanan D., Howarth P.H., Holgate S.T., Holloway J.W., et al. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 55 Suppl 2 (2000) S28-S31
14. Lima J.J., Zhang S., Grant A., Shao L., Tantisira K.G., Allayee H., et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med 173 (2006) 379-385
15. Kalayci O., Birben E., Sackesen C., Keskin O., Tahan F., Wechsler M.E., et al. ALOX5 promoter genotype, asthma severity and LTC production by eosinophils. Allergy 61 (2006) 97-103
16. Fowler S.J., Hall I.P., Wilson A.M., Wheatley A.P., and Lipworth B.J. 5-Lipoxygenase polymorphism and in-vivo response to leukotriene receptor antagonists. Eur J Clin Pharmacol 58 (2002) 187-190
17. Sayers I., and Hall I.P. Pharmacogenetic approaches in the treatment of asthma. Curr Allergy Asthma Rep 5 (2005) 101-108